CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

[1]  K. McColl,et al.  Eradication of Helicobacter pylori: an objective assessment of current therapies. , 1997, British journal of clinical pharmacology.

[2]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[3]  M. Blaser,et al.  Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. , 1997, Gastroenterology.

[4]  T. Furuta,et al.  Study of transmission routes of Helicobacter pylori in relation to seroprevalence of hepatitis A virus , 1997, Journal of clinical microbiology.

[5]  J. Goldstein,et al.  Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. , 1997, The Journal of pharmacology and experimental therapeutics.

[6]  L. Bertilsson,et al.  CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. , 1996, Pharmacogenetics.

[7]  T Ishizaki,et al.  Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population , 1996, Clinical pharmacology and therapeutics.

[8]  J. Balian,et al.  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.

[9]  R. Spiller,et al.  Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. , 1996, Gastroenterology.

[10]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[11]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  R. Hopkins,et al.  Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. , 1996, Gastroenterology.

[13]  A. Blum,et al.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. , 1996, Gastroenterology.

[14]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[15]  J. Walsh,et al.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. , 1995, The New England journal of medicine.

[16]  A. Blum,et al.  Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. , 1995, Gut.

[17]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[18]  M. Ingelman-Sundberg,et al.  Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe , 1995, Clinical pharmacology and therapeutics.

[19]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[20]  S. Miehlke,et al.  Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. , 1995, Gastroenterology.

[21]  J. Launay,et al.  Helicobacter pylori infection: Physiopathologic implication of Nα-methyl histamine , 1995 .

[22]  X. Fan,et al.  Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. , 1995, Journal of clinical pathology.

[23]  Y. Matsuzawa,et al.  Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. , 1994, The American journal of physiology.

[24]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[25]  J. Jansen,et al.  Basal serum gastrin concentrations before and after eradication elicobacter pylori infection measured by sequence specific radioimmunoassays , 1994, Alimentary pharmacology & therapeutics.

[26]  K. Sewing,et al.  Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase. , 1994, Gut.

[27]  M. Wolfe,et al.  The effect of recombinant cytokines on [14C]-aminopyrine accumulation by isolated canine parietal cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[28]  G. Strohmeyer,et al.  Effects of Helicobacter pylori on histamine and carbachol stimulated acid secretion by human parietal cells. , 1994, Gut.

[29]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.

[30]  S. V. van Deventer,et al.  Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. , 1994, Scandinavian journal of gastroenterology.

[31]  T. Andersson,et al.  Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. , 1994, Therapeutic drug monitoring.

[32]  R. Koehler,et al.  Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. , 1994, Gastroenterology.

[33]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[34]  Kaoru Kobayashi,et al.  Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. , 1992, Journal of chromatography.

[35]  K. Chiba,et al.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.

[36]  J. Crabtree,et al.  Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. , 1991, Gut.

[37]  D. Graham,et al.  Helicobacter pylori-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. , 1991, Gastroenterology.

[38]  M. Quina,et al.  Omeprazole in the treatment of peptic ulcers resistant to H2‐receptor antagonist , 1990, Alimentary pharmacology & therapeutics.

[39]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[40]  S. Brand,et al.  Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. , 1988, The Journal of clinical investigation.

[41]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[42]  W. Irvine,et al.  Radioimmunoassay of plasmagastrin in pernicious anaemia, achlorhydria without pernicious anaemia, hypochlorhydria, and in controls. , 1971, Lancet.

[43]  M. Kajimura,et al.  Effect of Helicobacter pylori infection on gastric juice pH. , 1998, Scandinavian journal of gastroenterology.

[44]  M. Classen,et al.  Gastrin secretion from primary cultures of rabbit antral G cells: stimulation by inflammatory cytokines. , 1996, Gastroenterology.

[45]  G. Sachs,et al.  The pharmacology of the gastric acid pump: the H+,K+ ATPase. , 1995, Annual review of pharmacology and toxicology.

[46]  G. Sachs,et al.  The gastric H+,K+-ATPase: the site of action of omeprazole. , 1989, Scandinavian journal of gastroenterology. Supplement.

[47]  P. Brandtzaeg,et al.  Immunohistochemical investigation of gastrin-producing cells (G cells).The distribution of g cells in resected human stomachs. , 1976, Scandinavian journal of gastroenterology.